PLASMA Act
S. 4741118th Congress

PLASMA Act

Introduced in the SenateSen. Thomas Tillis (R-NC)10 sections · 1 min read
Version: Introduced in Senate · Jul 23, 2024

Section 1. Short title

This Act may be cited as the Preserving Life-saving Access to Specialty Medicines in America Act or the PLASMA Act.

Section 2. Phase-in for plasma-derived products under manufacturer discount program

Section 1860D–14C(g)(4) of the Social Security Act (42 U.S.C. 1395w–114c(g)(4)) is amended—

(1) in subparagraph (A), in the matter preceding clause (i), by striking and (C) and inserting, (C), and (D);

(2) by redesignating subparagraphs (D) and (E) as subparagraphs (E) and (F), respectively; and

(3) by inserting after subparagraph (C) the following:

(i) In general

In the case of an applicable drug that is a plasma-derived product (as defined in clause (ii)), and that is marketed as of the date of enactment of this subparagraph and dispensed for an applicable beneficiary, the term discounted price means the specified plasma-derived product percent (as defined in clause (iii)) of the negotiated price of the applicable drug of the manufacturer.

(ii) Plasma-derived product

In this subparagraph, the term plasma-derived product means an applicable drug that is a biological product that is derived from human whole blood or plasma.

(iii) Specified plasma-derived product percent

In this subparagraph, the term specified plasma-derived product percent means, with respect to a year—

(I) for an applicable drug that is as a plasma-derived product dispensed for an applicable beneficiary who has not incurred costs, as determined in accordance with section 1860D–2(b)(4)(C), for covered part D drugs in the year that are equal to or exceed the annual out-of-pocket threshold specified in section 1860D–2(b)(4)(B)(i) for the year, the percent specified under subparagraph (B)(iii)(I) for such year; and

(II) for an applicable drug that is as a plasma-derived product dispensed for an applicable beneficiary who has incurred costs, as determined in accordance with section 1860D–2(b)(4)(C), for covered part D drugs in the year that are equal to or exceed the annual out-of-pocket threshold specified in section 1860D–2(b)(4)(B)(i) for the year, the percent specified under subparagraph (B)(iii)(II) for such year.

to ask questions about this bill.